Orion Portfolio Solutions LLC Trims Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Orion Portfolio Solutions LLC cut its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 13.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,418 shares of the company’s stock after selling 4,914 shares during the period. Orion Portfolio Solutions LLC’s holdings in Apellis Pharmaceuticals were worth $906,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of APLS. HighVista Strategies LLC grew its stake in Apellis Pharmaceuticals by 4.1% during the second quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock valued at $290,000 after acquiring an additional 300 shares in the last quarter. Amalgamated Bank boosted its holdings in Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after purchasing an additional 359 shares during the period. KBC Group NV grew its position in shares of Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after purchasing an additional 781 shares during the period. Finally, Wolverine Asset Management LLC bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth $27,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on APLS shares. Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price objective for the company. The Goldman Sachs Group dropped their price target on Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Evercore ISI upgraded shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Mizuho dropped their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research report on Thursday, October 24th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $49.94.

Apellis Pharmaceuticals Trading Up 1.4 %

NASDAQ APLS opened at $33.19 on Monday. The firm has a market cap of $4.13 billion, a PE ratio of -16.35 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $73.80. The stock has a 50-day moving average of $29.65 and a 200-day moving average of $34.72. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the previous year, the firm posted ($1.17) EPS. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).